Stronger Drug Approvals: New Rules for Accelerated Pathways
This act aims to enhance the safety of drugs approved through accelerated pathways. It means pharmaceutical companies will be required to confirm the effectiveness of their products more quickly and reliably, providing citizens with greater confidence in the medications they take. If effectiveness is not confirmed, the drug can be withdrawn from the market faster, and labels will clearly state the approval status.
Key points
Pharmaceutical companies must conduct mandatory studies to confirm the effectiveness of drugs approved via accelerated pathways before they reach the market.
If studies do not progress or effectiveness is not confirmed, the drug can be quickly withdrawn, protecting patients from ineffective treatments.
Labels for accelerated approval drugs will clearly state this status and the need for further studies, increasing patient awareness.
Penalties for lack of diligence in studies or untimely reporting are introduced to ensure greater corporate accountability.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.